2021 HFSA Annual Scientific Meeting

Course Details

All sessions and content listed below are available in this Educational Activity

Session 1: Crash and Burn: Cardiogenic Shock in 2021

Session 2: Sarcoidosis

Session 3: Psychosocial Evaluation for Advanced HF Therapies: Are we evaluating patients fairly?

Session 4: FDA Special Session: Focus on HFSA Research Network

Session 5: The Right Heart: No More the Forgotten Side

Session 6: Digesting EMPEROR-Preserved: The Evolving Treatment of HFpEF and Use of SGLT2i 

Session 7: Referral for Advanced Heart Failure

Session 8: Beyond PVR:  Assessing and Managing the Dysfunctional Right Ventricle (audio is poor -- sometimes low and sometimes high)

Session 9: Deep Learning for HF Medicine: A Practical Primer 

Session 10: Recent Advances and Update on Myocarditis

Session 11: Applying Genetics & Genomics in HF: Current Landscape & Future Directions

Session 12: Substance use in Tx and LVAD Candidates

Session 13: COVID and the HF Clinician

Session 14: Burned Out : Identifying and Managing Clinician Burnout and Mental Wellness 

Session 15: Late Breaking Clinical Trials I

Session 16: Cardio-oncology

Session 17: International Session - Universal Definition of HF

Session 18: Optimizing LVAD Management 

Session 19: Failing Organs in Patients with Advanced HF, Will a Cardiac Fix Fix the Rest?

Session 20: Innovation in Heart Transplant: The Future of the Field

Session 21: HFpEF 

Session 22: Role of Diet, Nutrition, & Body Composition in Patients with HF

Session 23: Dismantling Historical Systems of Inequity to Improve Access to Advanced Heart

Session 24: Failure Therapies for Diverse Populations 

Session 25: Pulmonary Arterial Hypertension: Providing Comprehensive Care Based on Risk

Session 26: Virtual Health

Session 27: Best of JCF and HF Journal Round Table

Session 28: Innovative Strategies for Better LVAD Outcomes

Session 29: Excellence in Translational Science

Session 30: "Reexamining the 2018 Change in Heart Transplant Allocation Decisions: Are We Better Off Now? 

Session 31: FDA Special Session - Focus on HFSA Research Network

Session 32: Defining Constructs of Heart Failure: Biomarkers to Symptoms

Session 33: Emerging Devices/Procedures for Heart Failure 

Session 34: Care Transitions: Methods, Medications, Metrics, and More!

Session 35: Debate: Optimal Medical Therapy for HFrEF, Death of HVAD, and Oral Inotropy

Session 36: Peripartum Cardiomyopathy: Is It Time To Update Our Definition

Session 37: JNC New Investigator Award (Basic Science / Clinical)

Session 38: Nursing New Investigator Award (Research / Clinical)

Session 39: Late Breaking Clinical Trials II 

Session 40: Clinical Conundrums (Multidisciplinary Case Discussion) 

Session 41: Revascularization in HF

Session 42: Unintended Side Effects: Polypharmacy, Adherence, & Financial Toxicity of Evolving GDMT for Heart Failure

Session 43: JNC and Nursing New Investigator Award Announcements and Hyde Park

Session 44: Cardiac Amyloidosis

Session 45: 2021 Plenary Session: Lessons for HF Care from the Pandemic: Imagining a Better New Normal